RxDoctor Payments Data

David Penn, MD

Vascular & Interventional Radiology · Stockbridge, GANPI 1760644355

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (41.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Angiodynamics, Inc. accounts for 62.9% of it on its own, with 32 other manufacturers making up the rest.

$15,509in general payments, 2019–2025

Across 211 payments — averaging $73.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$10K
  • Bard Peripheral Vascular, Inc.$700
  • Johnson & Johnson$654
  • W. L. Gore & Associates, Inc.$520
  • Medtronic$488
  • Endologix LLC$415
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$5,89938%
  • Education$3,21021%
  • Other$6,40041%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,509 in reported general payments places this provider in the 80th percentile of 120 vascular & interventional radiology providers in Georgia.

See all vascular & interventional radiology providers in Georgia

Medicare billing

Part B allowed, 2024
$225,124
Medicare patients
171
Services billed
741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$124,195
XareltoRivaroxaban26$26,013
Tobramycin Sulfate14$25,791
Varenicline Tartrate19$5,076
Cilostazol260$4,723
Pentoxifylline126$3,436
ClopidogrelClopidogrel Bisulfate172$1,872
Gabapentin117$1,075
Pantoprazole Sodium82$624
Esomeprazole Magnesium11$536
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$186
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$163
Famotidine20$123
Doxycycline Monohydrate13$119
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$367$124,195116 claims
Johnson & JohnsonXarelto$654$26,01326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 120 vascular & interventional radiology providers in Georgia.

Other vascular & interventional radiology in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →